Predictive value of circulating tumor cells positive for VEGFR expression in patients with advanced colorectal cancer undergoing treatment with FOLFOX plus bevacizumab.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e22026-e22026
Author(s):  
M. Jose Serrano ◽  
Francisco Gabriel Ortega ◽  
jose Antonio Lorente ◽  
Mayte Delgado ◽  
Jose Luis Puche
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Predictive Value ◽  
Advanced Colorectal Cancer

Biomarkers to predict the clinical efficacy of bevacizumab in advanced colorectal cancer: KRAS mutational status of circulating tumor cells.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e22030-e22030
Author(s):  
Marco Danova ◽  
Giuditta Comolli ◽  
Martina Torchio ◽  
Valerio Gristina ◽  
Alessandro Stefano Bertolini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Efficacy ◽  
Advanced Colorectal Cancer ◽  
Mutational Status

Genetic profiling of circulating tumor cells in patients with advanced colorectal cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e14113-e14113
Author(s):  
D. Ernst ◽  
I. Kubisch ◽  
A. de Albuquerque ◽  
S. Kaul ◽  
J. Boese-Landgraf ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Advanced Colorectal Cancer ◽  
Genetic Profiling

Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer

2020 ◽  
Vol 16 (18) ◽  
pp. 1289-1299
Author(s):  
Xiaohong Pan ◽  
Xiaoli Zhang
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Kras Mutation ◽  
Advanced Colorectal Cancer ◽  
Plasma Dna ◽  
Predictive Values ◽  
Early Risk ◽  
Colorectal Cancer Patients ◽  
Prognosis Indicator

Aim: Clinical management of colorectal cancer is challenging. Circulating tumor cells (CTCs) and DNA (ctDNA) are investigated to detect key KRAS mutation and for prognosis for risk stratifications. Materials & methods: 200 advance-stage patients with metastatic disease were selected and followed-up. Serial blood draws were used to quantify CTCs and ctDNA. Results: Both CTCs and ctDNA are strongly associated with colorectal cancer patients. The positive predictive values were 96.5 and 96.3% among CTCs and ctDNA, respectively, for all 200 patients using KRAS mutation. Specificity for healthy controls was 100%. As a prognosis indicator, results demonstrated that patients who had positive CTCs and plasma DNA had worse outcomes. Conclusion: Blood-based assessment of colorectal cancer shows promising results in early-risk stratifications.

scholarly journals KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Yuurin Kondo ◽  
Kazuhiko Hayashi ◽  
Kazuyuki Kawakami ◽  
Yukari Miwa ◽  
Hiroshi Hayashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Mutation Analysis ◽  
Kras Mutation

scholarly journals CELL MEDIATED IMMUNITY IN PATIENTS WITH STAGE II–IV COLORECTAL CANCER WITH OR WITHOUT CIRCULATING TUMOR CELLS

2020 ◽  
Vol 19 (4) ◽  
pp. 94-98
Author(s):  
E. Y. Zlatnik ◽  
A. O. Sitkovskaya ◽  
I. A. Novikova ◽  
E. S. Bondarenko ◽  
A. B. Sagakyants
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Stage Ii ◽  
Cell Mediated Immunity
Sign in / Sign up

Export Citation Format

Share Document